Zurich Cantonal Bank
VERV

Zurich Cantonal Bank’s Verve Therapeutics VERV Stock Holding History

Zurich Cantonal Bank’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,973
Closed -$89.5K – 2603
2025
Q2 		$89.5K Sell
7,973
-192
-2% -$1.09K ﹤0.01% 2397
2025
Q1 		$37.3K Sell
8,165
-25
-0.3% -$167 ﹤0.01% 2539
2024
Q4 		$46.2K Hold
8,190
– – ﹤0.01% 2562
2024
Q3 		$39.6K Hold
8,190
– – ﹤0.01% 2575
2024
Q2 		$40K Buy
8,190
+348
+4% +$2.19K ﹤0.01% 2561
2024
Q1 		$104K Sell
7,842
-5,019
-39% -$66.6K ﹤0.01% 2383
2023
Q4 		$179K Buy
12,861
+5,746
+81% +$71.2K ﹤0.01% 2145
2023
Q3 		$94.3K Hold
7,115
– – ﹤0.01% 2376
2023
Q2 		$133K Buy
7,115
+2,349
+49% +$39.1K ﹤0.01% 2184
2023
Q1 		$68.7K Hold
4,766
– – ﹤0.01% 2487
2022
Q4 		$92.2K Buy
4,766
+154
+3% +$4.08K ﹤0.01% 2320
2022
Q3 		$158K Buy
4,612
+1,693
+58% +$54K ﹤0.01% 1907
2022
Q2 		$45K Hold
2,919
– – ﹤0.01% 2633
2022
Q1 		$67K Buy
+2,919
New +$83.4K ﹤0.01% 2448

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Zurich Cantonal Bank's VERV Position: Q3 2025 in Review

Zurich Cantonal Bank sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 7,973 shares — an estimated $89.5K sold.

Zurich Cantonal Bank first reported a position in VERV in Q1 2022 and held it in 14 quarters. The position peaked at $179K in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Zurich Cantonal Bank reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 7,973 Verve Therapeutics shares in Q3 2025, an estimated $89.5K.
  • Zurich Cantonal Bank first reported a position in Verve Therapeutics in Q1 2022 and held it in 14 quarters.
  • Zurich Cantonal Bank's Verve Therapeutics position peaked at $179K in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Zurich Cantonal Bank's 13F filing for Q3 2025, filed 14 Nov 2025.